scm logo

We participated in ‘Biologics World Korea (5th Annual Biologics World Korea 2016)’, a conference focused on mass production and manufacturing of biologics and biosimilars. The event, which was attended by experts leading the biologics industry from Korea and other countries around the world, was successfully held at the Novotel Hotel in Gangnam, Seoul, for two days from June 29. And Executives and technical staff from bio-drug-related companies and high-tech bio-technology companies from around the world gathered to discuss manufacturing strategies, best practices for upstream and downstream processes, and the latest technologies. 

The main topics of discussion were ◆the best practices of manufacturing Antibody Combinations (ADC) ◆ problems and strategies of the cell therapy bioprocess ◆ new technologies of bioprocess, ◆ continuous manufacturing, ◆ cell line engineering, ◆ Various discussions were held in East Asia, including Korea, Japan, and Taiwan, including the introduction of a Contract Manufacturing Organizations (CMO).

At the event, our CEO Song Sun-uk presented the theme of 'Manufacture of Clinical-grade SCM-CGH from Single Collections Base on the Subfraction Culture Method' on the morning of the 30th, the last day of the event.

In April, the company attracted 10 billion won worth of secondary funding from Korea Investment Partners, NHN Investment, DSC Investment, and KDB Capital, and received approval from the Ministry of Food and Drug Safety to examine the efficacy of fresh homogeneous stem cell therapy (SCM-CGH) for Dongwol Graft versus host disease (GVHD).